UNknown的个人主页 - 老虎社区

UNknown

UNknown

暂无个人介绍

IP属地：未知

126关注

9粉丝

0主题

0勋章

2021-12-15

Ok thanks

Uber jumped nearly 7% in morning trading as it cooperated with Clear Secure

2021-12-13

Like

Qualcomm leans into cameras, gaming with new flagship smartphone chip

2021-12-01

Ok Thanks

Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates

2021-11-30

Great

Big tech shares jumped in morning trading

2021-11-27

Good thanks

Prediction: These 2 Stocks Will Soar in 2022

2021-11-23

Thanks

Nasdaq and S&P 500 end down after hitting record highs

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4093776015978190,"uuid":"4093776015978190","gmtCreate":1630673150500,"gmtModify":1636869434842,"name":"UNknown","pinyin":"unknown","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/544ab1c11c2e3063efc979d573c9bf0f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":9,"headSize":126,"tweetSize":23,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.26%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":607178331,"gmtCreate":1639518553383,"gmtModify":1639518575321,"author":{"id":"4093776015978190","authorId":"4093776015978190","name":"UNknown","avatar":"https://static.tigerbbs.com/544ab1c11c2e3063efc979d573c9bf0f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok thanks","listText":"Ok thanks","text":"Ok thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607178331","repostId":"1195286060","repostType":4,"repost":{"id":"1195286060","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639495787,"share":"https://www.laohu8.com/m/news/1195286060?lang=&edition=full","pubTime":"2021-12-14 23:29","market":"us","language":"en","title":"Uber jumped nearly 7% in morning trading as it cooperated with Clear Secure","url":"https://stock-news.laohu8.com/highlight/detail?id=1195286060","media":"Tiger Newspress","summary":"Uber jumped nearly 7% in morning trading as it cooperated with Clear Secure.Clear Secure (YOU) and U","content":"<p>Uber jumped nearly 7% in morning trading as it cooperated with Clear Secure.<img src=\"https://static.tigerbbs.com/81fdbb81086badeece485e7e1485a156\" tg-width=\"768\" tg-height=\"562\" width=\"100%\" height=\"auto\">Clear Secure (YOU) and Uber (UBER) have announced a partnership that will integrate Uber's ride platform directly into the Clear app's \"Home to Gate\" feature. With this partnership, Clear app users will be able to use the Home To Gate feature and its data-driven insights to find out exactly when to leave for their flight and reserve an Uber ride ahead of time - creating a more seamless, predictable travel experience.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Uber jumped nearly 7% in morning trading as it cooperated with Clear Secure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUber jumped nearly 7% in morning trading as it cooperated with Clear Secure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-14 23:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Uber jumped nearly 7% in morning trading as it cooperated with Clear Secure.<img src=\"https://static.tigerbbs.com/81fdbb81086badeece485e7e1485a156\" tg-width=\"768\" tg-height=\"562\" width=\"100%\" height=\"auto\">Clear Secure (YOU) and Uber (UBER) have announced a partnership that will integrate Uber's ride platform directly into the Clear app's \"Home to Gate\" feature. With this partnership, Clear app users will be able to use the Home To Gate feature and its data-driven insights to find out exactly when to leave for their flight and reserve an Uber ride ahead of time - creating a more seamless, predictable travel experience.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBER":"优步"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195286060","content_text":"Uber jumped nearly 7% in morning trading as it cooperated with Clear Secure.Clear Secure (YOU) and Uber (UBER) have announced a partnership that will integrate Uber's ride platform directly into the Clear app's \"Home to Gate\" feature. With this partnership, Clear app users will be able to use the Home To Gate feature and its data-driven insights to find out exactly when to leave for their flight and reserve an Uber ride ahead of time - creating a more seamless, predictable travel experience.","news_type":1},"isVote":1,"tweetType":1,"viewCount":608,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604335713,"gmtCreate":1639347381504,"gmtModify":1639347381660,"author":{"id":"4093776015978190","authorId":"4093776015978190","name":"UNknown","avatar":"https://static.tigerbbs.com/544ab1c11c2e3063efc979d573c9bf0f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604335713","repostId":"2188532153","repostType":2,"repost":{"id":"2188532153","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1638314580,"share":"https://www.laohu8.com/m/news/2188532153?lang=&edition=full","pubTime":"2021-12-01 07:23","market":"us","language":"en","title":"Qualcomm leans into cameras, gaming with new flagship smartphone chip","url":"https://stock-news.laohu8.com/highlight/detail?id=2188532153","media":"Reuters","summary":"Nov 30 (Reuters) - Qualcomm Inc on Tuesday released its new top-tier smartphone chip aimed at premiu","content":"<p>Nov 30 (Reuters) - Qualcomm Inc on Tuesday released its new top-tier smartphone chip aimed at premium-priced Android phones with features like sharper photos and graphics than handsets using chips from rivals.</p>\n<p>The San Diego, California-based company is the biggest supplier of the chips at the heart of many Android phones, competing against rivals such as Taiwan's MediaTek Inc and Samsung Electronics Co Ltd , which uses Qualcomm chips in some of its phones but self-supplies chips for some models.</p>\n<p>The Snapdragon 8 Gen 1 chip released Tuesday will have similar computing cores to rivals like MediaTek, which this month announced a chip aimed at premium phones. But almost every other part of the chip are custom designed by Qualcomm, including those playing a role in the visual quality of photos and graphics-intensive apps like games.</p>\n<p>Alex Katouzian, senior vice president and general manager of mobile, compute and infrastructure for Qualcomm, said the company has been crafting software that will let handset makers tap deeper into those parts of the chip.</p>\n<p>\"It's not just saying, I've got the biggest CPU and I can hit a benchmark that lasts <a href=\"https://laohu8.com/S/AONE.U\">one</a> minute,\" Katouzian told Reuters in an interview. \"We have all these capabilities, and it's really about the user experience. That's going to make a difference.\"</p>\n<p>Qualcomm said that more than a dozen phone makers - including Xiaomi Corp , Sony Group Corp and Honor, the brand spun out of Huawei Technologies Group Ltd- have signed up to use the new chips and that phones featuring it will be on the market before the end of the year.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qualcomm leans into cameras, gaming with new flagship smartphone chip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQualcomm leans into cameras, gaming with new flagship smartphone chip\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-01 07:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nov 30 (Reuters) - Qualcomm Inc on Tuesday released its new top-tier smartphone chip aimed at premium-priced Android phones with features like sharper photos and graphics than handsets using chips from rivals.</p>\n<p>The San Diego, California-based company is the biggest supplier of the chips at the heart of many Android phones, competing against rivals such as Taiwan's MediaTek Inc and Samsung Electronics Co Ltd , which uses Qualcomm chips in some of its phones but self-supplies chips for some models.</p>\n<p>The Snapdragon 8 Gen 1 chip released Tuesday will have similar computing cores to rivals like MediaTek, which this month announced a chip aimed at premium phones. But almost every other part of the chip are custom designed by Qualcomm, including those playing a role in the visual quality of photos and graphics-intensive apps like games.</p>\n<p>Alex Katouzian, senior vice president and general manager of mobile, compute and infrastructure for Qualcomm, said the company has been crafting software that will let handset makers tap deeper into those parts of the chip.</p>\n<p>\"It's not just saying, I've got the biggest CPU and I can hit a benchmark that lasts <a href=\"https://laohu8.com/S/AONE.U\">one</a> minute,\" Katouzian told Reuters in an interview. \"We have all these capabilities, and it's really about the user experience. That's going to make a difference.\"</p>\n<p>Qualcomm said that more than a dozen phone makers - including Xiaomi Corp , Sony Group Corp and Honor, the brand spun out of Huawei Technologies Group Ltd- have signed up to use the new chips and that phones featuring it will be on the market before the end of the year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4561":"索罗斯持仓","01810":"小米集团-W","BK4527":"明星科技股","BK4534":"瑞士信贷持仓","BK4532":"文艺复兴科技持仓","QCOM":"高通","BK4512":"苹果概念","BK4141":"半导体产品","BK4515":"5G概念","BK4554":"元宇宙及AR概念"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188532153","content_text":"Nov 30 (Reuters) - Qualcomm Inc on Tuesday released its new top-tier smartphone chip aimed at premium-priced Android phones with features like sharper photos and graphics than handsets using chips from rivals.\nThe San Diego, California-based company is the biggest supplier of the chips at the heart of many Android phones, competing against rivals such as Taiwan's MediaTek Inc and Samsung Electronics Co Ltd , which uses Qualcomm chips in some of its phones but self-supplies chips for some models.\nThe Snapdragon 8 Gen 1 chip released Tuesday will have similar computing cores to rivals like MediaTek, which this month announced a chip aimed at premium phones. But almost every other part of the chip are custom designed by Qualcomm, including those playing a role in the visual quality of photos and graphics-intensive apps like games.\nAlex Katouzian, senior vice president and general manager of mobile, compute and infrastructure for Qualcomm, said the company has been crafting software that will let handset makers tap deeper into those parts of the chip.\n\"It's not just saying, I've got the biggest CPU and I can hit a benchmark that lasts one minute,\" Katouzian told Reuters in an interview. \"We have all these capabilities, and it's really about the user experience. That's going to make a difference.\"\nQualcomm said that more than a dozen phone makers - including Xiaomi Corp , Sony Group Corp and Honor, the brand spun out of Huawei Technologies Group Ltd- have signed up to use the new chips and that phones featuring it will be on the market before the end of the year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609544749,"gmtCreate":1638314157014,"gmtModify":1638314157014,"author":{"id":"4093776015978190","authorId":"4093776015978190","name":"UNknown","avatar":"https://static.tigerbbs.com/544ab1c11c2e3063efc979d573c9bf0f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok&nbsp;Thanks&nbsp;","listText":"Ok&nbsp;Thanks&nbsp;","text":"Ok Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609544749","repostId":"1192203085","repostType":4,"repost":{"id":"1192203085","pubTimestamp":1638273550,"share":"https://www.laohu8.com/m/news/1192203085?lang=&edition=full","pubTime":"2021-11-30 19:59","market":"us","language":"en","title":"Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates","url":"https://stock-news.laohu8.com/highlight/detail?id=1192203085","media":"The Wall Street Journal","summary":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA ","content":"<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p>\n<p>Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p>\n<p>Separate testing of another authorized Covid-19 antibody drug cocktail, from&nbsp;Eli Lilly&amp; Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p>\n<p>The findings are the early results of researchers’ race to assess the impact of the&nbsp;new Omicron variant&nbsp;on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p>\n<p>Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p>\n<p>Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p>\n<p>They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p>\n<p>The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former&nbsp;President Donald Trump credited Regeneron’s drug&nbsp;with his speedy recovery from Covid-19.</p>\n<p>Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p>\n<p>If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p>\n<p>One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p>\n<p>The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p>\n<p>“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p>\n<p>Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p>\n<p>More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p>\n<p>Lilly is in the process of testing the new variant against its drug, a combination of&nbsp;two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p>\n<p>She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p>\n<p>“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p>\n<p>A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including&nbsp;Vir Biotechnology&nbsp;Inc.&nbsp;and GlaxoSmithKline PLC, whose drug&nbsp;sotrovimab was authorized for emergency use&nbsp;earlier this year.</p>\n<p>Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p>\n<p>Adagio Therapeutics&nbsp;Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p>\n<p>Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p>\n<p>Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p>\n<p>Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p>\n<p>“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p>\n<p>It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p>\n<p>“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p>\n<p>Antiviral drugs, including pills from&nbsp;Merck&amp; Co. and partner Ridgeback Biotherapeutics LP and from&nbsp;Pfizer&nbsp;Inc.&nbsp;that are being&nbsp;evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p>\n<p>Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have&nbsp;reduced the risk of hospitalization&nbsp;if taken early enough.</p>\n<p>“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p>\n<p>Pfizer and Merck said they expect their drugs to be effective against Omicron.</p>\n<p>Gilead SciencesInc.&nbsp;also said it expects&nbsp;Veklury, its antiviral drug&nbsp;used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCovid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests ...</p>\n\n<a href=\"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","LLY":"礼来"},"source_url":"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192203085","content_text":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.\nSeparate testing of another authorized Covid-19 antibody drug cocktail, from Eli Lilly& Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.\nThe findings are the early results of researchers’ race to assess the impact of the new Omicron variant on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.\nResearchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.\nMonoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.\nThey are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.\nThe drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former President Donald Trump credited Regeneron’s drug with his speedy recovery from Covid-19.\nRegeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.\nAntiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.\nIf final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.\nOne of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.\nThe Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.\n“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”\nScientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.\nMore comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.\nLilly is in the process of testing the new variant against its drug, a combination of two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.\nShe declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.\n“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”\nA rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including Vir Biotechnology Inc. and GlaxoSmithKline PLC, whose drug sotrovimab was authorized for emergency use earlier this year.\nFred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.\nAdagio Therapeutics Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.\nVir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.\nOmicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.\nVir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.\n“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.\nIt will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.\n“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”\nAntiviral drugs, including pills from Merck& Co. and partner Ridgeback Biotherapeutics LP and from Pfizer Inc. that are being evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.\nDoctors and patients have been looking forward to authorization of the pills, which in clinical trials have reduced the risk of hospitalization if taken early enough.\n“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.\nPfizer and Merck said they expect their drugs to be effective against Omicron.\nGilead SciencesInc. also said it expects Veklury, its antiviral drug used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.","news_type":1},"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609055438,"gmtCreate":1638227210475,"gmtModify":1638227210655,"author":{"id":"4093776015978190","authorId":"4093776015978190","name":"UNknown","avatar":"https://static.tigerbbs.com/544ab1c11c2e3063efc979d573c9bf0f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609055438","repostId":"1182524223","repostType":4,"repost":{"id":"1182524223","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197006,"share":"https://www.laohu8.com/m/news/1182524223?lang=&edition=full","pubTime":"2021-11-29 22:43","market":"us","language":"en","title":"Big tech shares jumped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1182524223","media":"Tiger Newspress","summary":"Big tech shares jumped in morning trading.Apple,Microsoft,Amazon,Alphabet and Meta Platforms climbed","content":"<p>Big tech shares jumped in morning trading.Apple,Microsoft,Amazon,Alphabet&nbsp;and&nbsp;Meta&nbsp;Platforms&nbsp;climbed between 1% and 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/e646cfb67f62c007db16ed52e6712cd4\" tg-width=\"406\" tg-height=\"299\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Big tech shares jumped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBig tech shares jumped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-29 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Big tech shares jumped in morning trading.Apple,Microsoft,Amazon,Alphabet&nbsp;and&nbsp;Meta&nbsp;Platforms&nbsp;climbed between 1% and 2%.</p>\n<p><img src=\"https://static.tigerbbs.com/e646cfb67f62c007db16ed52e6712cd4\" tg-width=\"406\" tg-height=\"299\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","GOOGL":"谷歌A","MSFT":"微软","AMZN":"亚马逊"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182524223","content_text":"Big tech shares jumped in morning trading.Apple,Microsoft,Amazon,Alphabet and Meta Platforms climbed between 1% and 2%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877499076,"gmtCreate":1637968372606,"gmtModify":1637968796763,"author":{"id":"4093776015978190","authorId":"4093776015978190","name":"UNknown","avatar":"https://static.tigerbbs.com/544ab1c11c2e3063efc979d573c9bf0f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good thanks&nbsp;","listText":"Good thanks&nbsp;","text":"Good thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877499076","repostId":"2186334897","repostType":4,"repost":{"id":"2186334897","pubTimestamp":1637936520,"share":"https://www.laohu8.com/m/news/2186334897?lang=&edition=full","pubTime":"2021-11-26 22:22","market":"us","language":"en","title":"Prediction: These 2 Stocks Will Soar in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2186334897","media":"Motley Fool","summary":"These two stocks were battered in 2021, but 2022 could be a different story.","content":"<p>The stock market has been performing amazingly well in 2021. The <b>SPDR S&amp;P 500 ETF</b>&nbsp;has been at or near an all-time high all year, with its biggest drop being in October when it fell 5%.&nbsp;But not all stocks have followed a similar path. Some have fallen up to 70% off their all-time highs. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> of the biggest names that got crushed in 2021 were <b>Pinterest</b> (NYSE:PINS) and <b>Lemonade</b> (NYSE:LMND) -- falling 52% and 72% off their highs, respectively.</p>\n<p>Despite their falls, both companies have strong potential and made substantial business progress while their stocks were pounded. This progress might pay off in 2022, which could send their stocks up to all-time highs.</p>\n<h2>1. Pinterest is not an MAU story</h2>\n<p>Shares of the social media company have gotten hammered in 2021, slowly falling from the highs they hit in the first few months of the year. The company was up against tough 2020 comparables in its earnings reports. The use of Pinterest rose drastically during the COVID-19 pandemic, but as the world slowly reopened, the company saw slower growth internationally and even a decreasing user count in the U.S.</p>\n<p>In Q3 2020, for example, Pinterest has 98 million U.S. monthly active users (MAUs), but that decreased to 89 million in Q3 2021. In Q4 2020, Pinterest saw international MAU grow by 46%, compared to Q3 2021 growth of just 4%.</p>\n<p>While many investors worry about this declining growth, this isn't the primary key to success for Pinterest. The real opportunity for Pinterest is in the increased monetization of its MAUs. Pinterest has plenty of room for expansion of its average revenue per user (ARPU), especially when its ARPU of $1.41 is compared to other social media stocks. <b>Snapchat</b> (NYSE:SNAP) has an ARPU of $3.49, and <b><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a></b>' (NASDAQ:FB) ARPU is a whopping $10.</p>\n<p>The company has made important strides during 2021 to increase this monetization. One of those was Pinterest TV -- where creators can sell products from a video -- as well as efforts to make it easier for users to add items to a cart to buy later.</p>\n<p>This increased effort makes advertising on Pinterest more valuable to advertisers, and if these efforts are effective at increasing its ARPU in 2022, investors could see accelerating revenue growth. Currently, the company is growing ARPU at 37% year over year, but the company has the potential to hasten this growth. If the improved efforts are successful, Pinterest could experience significant revenue growth, which could finally make Pinterest a favorable investment again in 2022 and send shares soaring.</p>\n<h2>2. Lemonade's future is bright despite current losses</h2>\n<p>Like Pinterest, shares of the AI-based insurance company have been hammered in 2021. Almost six months after its initial public offering (IPO) in July 2020, the company saw shares skyrocket, jumping over 120% by the start of 2021. However, the hype of the IPO faded, and a tough first quarter due to the Texas freeze (failures in the natural gas infrastructure system that nearly halved the state's gas production) started a downturn that resulted in shares falling 71% off its all-time high.</p>\n<p>The Texas freeze hit Lemonade's net loss ratio, which shows how much the company has to pay in claims for how much it earns in premiums. In Q1, Lemonade's loss ratio reached 121%, meaning that the company paid out significantly more than the money it made in claims (not the best business model). Since Q1, its net loss has decreased, but it is still higher than what the company is aiming for. In Q3, the company's loss ratio was 77%, but the company says its loss ratio should be under 75% in the long term.</p>\n<p>Part of the reason the loss ratio was above 75% in Q3 was because of the rollout of its newer products, like car and pet insurance. The AI for Lemonade's newer products is still being fine-tuned, which is currently resulting in a higher net loss ratio for those products. Yet, despite the loss ratios being high, they are improving rapidly. The pet loss ratio improved by 4 percentage points sequentially, while the homeowners' loss ratio improved by 52 percentage points year over year.</p>\n<p>Clearly, there are trends showing that Lemonade's AI is getting more accurate with its newer products. And as these products mature and the AI gets more precise, investors will likely see these loss ratios improve substantially. The loss ratio has the potential to fall below the 75% threshold, which could help Lemonade rise again and turn investor sentiment positively toward the company.</p>\n<p>The bottom line for both companies is that investors fell out of love with them. Since the reasons they lost hype do not fully represent the company's success, the tide could turn in 2022. If each company's investments into its business in 2021 pay off, today might be a nice buying opportunity to reap benefits going into the new year.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prediction: These 2 Stocks Will Soar in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrediction: These 2 Stocks Will Soar in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/26/prediction-these-two-stocks-will-soar-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market has been performing amazingly well in 2021. The SPDR S&P 500 ETF has been at or near an all-time high all year, with its biggest drop being in October when it fell 5%. But not all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/26/prediction-these-two-stocks-will-soar-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LMND":"Lemonade, Inc.","BK4548":"巴美列捷福持仓","BK4107":"财产与意外伤害保险","BK4554":"元宇宙及AR概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BK4507":"流媒体概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4525":"远程办公概念","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4524":"宅经济概念","BK4508":"社交媒体","BK4527":"明星科技股","PINS":"Pinterest, Inc.","BK4077":"互动媒体与服务","BK4550":"红杉资本持仓","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4549":"软银资本持仓"},"source_url":"https://www.fool.com/investing/2021/11/26/prediction-these-two-stocks-will-soar-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186334897","content_text":"The stock market has been performing amazingly well in 2021. The SPDR S&P 500 ETF has been at or near an all-time high all year, with its biggest drop being in October when it fell 5%. But not all stocks have followed a similar path. Some have fallen up to 70% off their all-time highs. Two of the biggest names that got crushed in 2021 were Pinterest (NYSE:PINS) and Lemonade (NYSE:LMND) -- falling 52% and 72% off their highs, respectively.\nDespite their falls, both companies have strong potential and made substantial business progress while their stocks were pounded. This progress might pay off in 2022, which could send their stocks up to all-time highs.\n1. Pinterest is not an MAU story\nShares of the social media company have gotten hammered in 2021, slowly falling from the highs they hit in the first few months of the year. The company was up against tough 2020 comparables in its earnings reports. The use of Pinterest rose drastically during the COVID-19 pandemic, but as the world slowly reopened, the company saw slower growth internationally and even a decreasing user count in the U.S.\nIn Q3 2020, for example, Pinterest has 98 million U.S. monthly active users (MAUs), but that decreased to 89 million in Q3 2021. In Q4 2020, Pinterest saw international MAU grow by 46%, compared to Q3 2021 growth of just 4%.\nWhile many investors worry about this declining growth, this isn't the primary key to success for Pinterest. The real opportunity for Pinterest is in the increased monetization of its MAUs. Pinterest has plenty of room for expansion of its average revenue per user (ARPU), especially when its ARPU of $1.41 is compared to other social media stocks. Snapchat (NYSE:SNAP) has an ARPU of $3.49, and Meta Platforms' (NASDAQ:FB) ARPU is a whopping $10.\nThe company has made important strides during 2021 to increase this monetization. One of those was Pinterest TV -- where creators can sell products from a video -- as well as efforts to make it easier for users to add items to a cart to buy later.\nThis increased effort makes advertising on Pinterest more valuable to advertisers, and if these efforts are effective at increasing its ARPU in 2022, investors could see accelerating revenue growth. Currently, the company is growing ARPU at 37% year over year, but the company has the potential to hasten this growth. If the improved efforts are successful, Pinterest could experience significant revenue growth, which could finally make Pinterest a favorable investment again in 2022 and send shares soaring.\n2. Lemonade's future is bright despite current losses\nLike Pinterest, shares of the AI-based insurance company have been hammered in 2021. Almost six months after its initial public offering (IPO) in July 2020, the company saw shares skyrocket, jumping over 120% by the start of 2021. However, the hype of the IPO faded, and a tough first quarter due to the Texas freeze (failures in the natural gas infrastructure system that nearly halved the state's gas production) started a downturn that resulted in shares falling 71% off its all-time high.\nThe Texas freeze hit Lemonade's net loss ratio, which shows how much the company has to pay in claims for how much it earns in premiums. In Q1, Lemonade's loss ratio reached 121%, meaning that the company paid out significantly more than the money it made in claims (not the best business model). Since Q1, its net loss has decreased, but it is still higher than what the company is aiming for. In Q3, the company's loss ratio was 77%, but the company says its loss ratio should be under 75% in the long term.\nPart of the reason the loss ratio was above 75% in Q3 was because of the rollout of its newer products, like car and pet insurance. The AI for Lemonade's newer products is still being fine-tuned, which is currently resulting in a higher net loss ratio for those products. Yet, despite the loss ratios being high, they are improving rapidly. The pet loss ratio improved by 4 percentage points sequentially, while the homeowners' loss ratio improved by 52 percentage points year over year.\nClearly, there are trends showing that Lemonade's AI is getting more accurate with its newer products. And as these products mature and the AI gets more precise, investors will likely see these loss ratios improve substantially. The loss ratio has the potential to fall below the 75% threshold, which could help Lemonade rise again and turn investor sentiment positively toward the company.\nThe bottom line for both companies is that investors fell out of love with them. Since the reasons they lost hype do not fully represent the company's success, the tide could turn in 2022. If each company's investments into its business in 2021 pay off, today might be a nice buying opportunity to reap benefits going into the new year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":276,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875108597,"gmtCreate":1637622339591,"gmtModify":1637622339697,"author":{"id":"4093776015978190","authorId":"4093776015978190","name":"UNknown","avatar":"https://static.tigerbbs.com/544ab1c11c2e3063efc979d573c9bf0f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875108597","repostId":"2185306806","repostType":4,"repost":{"id":"2185306806","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1637620044,"share":"https://www.laohu8.com/m/news/2185306806?lang=&edition=full","pubTime":"2021-11-23 06:27","market":"us","language":"en","title":"Nasdaq and S&P 500 end down after hitting record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=2185306806","media":"Reuters","summary":"* Apple hits record high, JPM sees iPhone supply improving. Nov 22  - The S&P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.The Dow Jones Industrial Average ended slightly higher.Climbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late ","content":"<p>* Financials rally on rate hike expectations</p>\n<p>* Higher Treasury yields pressure tech stocks</p>\n<p>* Apple hits record high, JPM sees iPhone supply improving</p>\n<p>Nov 22 (Reuters) - The S&amp;P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.</p>\n<p>The Dow Jones Industrial Average ended slightly higher.</p>\n<p>Climbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late in the session.</p>\n<p>Apple ended up 0.3%, its highest closing level ever, after rising over 3% earlier in the day. JPMorgan flagged possible improvements to the supply of the iPhone 13 in coming months.</p>\n<p>Microsoft ended down almost 1% after earlier rising almost 2%.</p>\n<p>\"The market is nervous. We know we have Powell, but that doesn't help with the inflation issue,\" said Dennis Dick, a trader at Bright Trading LLC. \"Under the hood, growth tech got hit all day, and then all of tech got hit at the end.\"</p>\n<p>Powell's nomination was welcomed by many investors hoping for no big changes in the Fed as it guides the economy through a recovery from the pandemic. The central bank is set to herald a return to pre-pandemic policy by end-2022.</p>\n<p>Fed Governor Lael Brainard, who was the other top candidate for the job, will be vice chair, the White House said.</p>\n<p>\"Markets like predictability. ... While Brainard may have been a fine choice, the markets would not know what to expect from her even though the general consensus was that it meant lower rates for longer,\" said Randy Frederick, managing director of trading and derivatives at Charles Schwab in Austin, Texas.</p>\n<p>The S&amp;P 500 banks index rallied 2%, tracking a surge in Treasury yields as investors priced in policy tightening by the first half of 2022. Wells Fargo &amp; Co rose over 3% and was among the strongest major Wall Street banks.</p>\n<p>Futures contracts tied to the Fed's policy rate indicated that money markets are now expecting the U.S. central bank to raise interest rates by 25 basis points by next June versus a previous estimate of July.</p>\n<p>The Dow Jones Industrial Average rose 0.05% to end at 35,619.25 points, while the S&amp;P 500 lost 0.32% to 4,682.94.</p>\n<p>The Nasdaq Composite dropped 1.26% to 15,854.76.</p>\n<p>The S&amp;P 500 value index climbed 0.6%, strongly outperforming the S&amp;P 500 growth index's 1% dip.</p>\n<p>In extended trade, <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications fell 3% after the video-conferencing company posted quarterly revenue that beat expectations.</p>\n<p>Investors were awaiting a slew of economic data this week, including IHS business activity readings, personal consumption expenditure, and minutes of the Fed's latest meeting.</p>\n<p>In Monday's session, Amazon fell 2.8% and Alphabet declined 1.8%, both weighing heavily on the Nasdaq.</p>\n<p>Tesla Inc gained 1.7% after CEO Elon Musk tweeted that the Model S Plaid will \"probably\" be coming to China around March. The stock has almost recovered from a steep selloff earlier this month that started after Musk polled <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> users about whether he should sell some of his shares in the electric car maker.</p>\n<p>Activision Blizzard slipped 0.3% after a media report that the video game publisher's chief executive, Bobby Kotick, would consider leaving if he could not quickly address concerns about company culture.</p>\n<p>The S&amp;P 500 has now gained about 25% in 2021, while the Nasdaq is up 23%.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.76-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 52 new 52-week highs and 11 new lows; the Nasdaq Composite recorded 138 new highs and 507 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, compared with the 11.1 billion average for the full session over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq and S&P 500 end down after hitting record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq and S&P 500 end down after hitting record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-11-23 06:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Financials rally on rate hike expectations</p>\n<p>* Higher Treasury yields pressure tech stocks</p>\n<p>* Apple hits record high, JPM sees iPhone supply improving</p>\n<p>Nov 22 (Reuters) - The S&amp;P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.</p>\n<p>The Dow Jones Industrial Average ended slightly higher.</p>\n<p>Climbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late in the session.</p>\n<p>Apple ended up 0.3%, its highest closing level ever, after rising over 3% earlier in the day. JPMorgan flagged possible improvements to the supply of the iPhone 13 in coming months.</p>\n<p>Microsoft ended down almost 1% after earlier rising almost 2%.</p>\n<p>\"The market is nervous. We know we have Powell, but that doesn't help with the inflation issue,\" said Dennis Dick, a trader at Bright Trading LLC. \"Under the hood, growth tech got hit all day, and then all of tech got hit at the end.\"</p>\n<p>Powell's nomination was welcomed by many investors hoping for no big changes in the Fed as it guides the economy through a recovery from the pandemic. The central bank is set to herald a return to pre-pandemic policy by end-2022.</p>\n<p>Fed Governor Lael Brainard, who was the other top candidate for the job, will be vice chair, the White House said.</p>\n<p>\"Markets like predictability. ... While Brainard may have been a fine choice, the markets would not know what to expect from her even though the general consensus was that it meant lower rates for longer,\" said Randy Frederick, managing director of trading and derivatives at Charles Schwab in Austin, Texas.</p>\n<p>The S&amp;P 500 banks index rallied 2%, tracking a surge in Treasury yields as investors priced in policy tightening by the first half of 2022. Wells Fargo &amp; Co rose over 3% and was among the strongest major Wall Street banks.</p>\n<p>Futures contracts tied to the Fed's policy rate indicated that money markets are now expecting the U.S. central bank to raise interest rates by 25 basis points by next June versus a previous estimate of July.</p>\n<p>The Dow Jones Industrial Average rose 0.05% to end at 35,619.25 points, while the S&amp;P 500 lost 0.32% to 4,682.94.</p>\n<p>The Nasdaq Composite dropped 1.26% to 15,854.76.</p>\n<p>The S&amp;P 500 value index climbed 0.6%, strongly outperforming the S&amp;P 500 growth index's 1% dip.</p>\n<p>In extended trade, <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications fell 3% after the video-conferencing company posted quarterly revenue that beat expectations.</p>\n<p>Investors were awaiting a slew of economic data this week, including IHS business activity readings, personal consumption expenditure, and minutes of the Fed's latest meeting.</p>\n<p>In Monday's session, Amazon fell 2.8% and Alphabet declined 1.8%, both weighing heavily on the Nasdaq.</p>\n<p>Tesla Inc gained 1.7% after CEO Elon Musk tweeted that the Model S Plaid will \"probably\" be coming to China around March. The stock has almost recovered from a steep selloff earlier this month that started after Musk polled <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> users about whether he should sell some of his shares in the electric car maker.</p>\n<p>Activision Blizzard slipped 0.3% after a media report that the video game publisher's chief executive, Bobby Kotick, would consider leaving if he could not quickly address concerns about company culture.</p>\n<p>The S&amp;P 500 has now gained about 25% in 2021, while the Nasdaq is up 23%.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.76-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 52 new 52-week highs and 11 new lows; the Nasdaq Composite recorded 138 new highs and 507 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, compared with the 11.1 billion average for the full session over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SPY":"标普500ETF","IVV":"标普500指数ETF","BK4534":"瑞士信贷持仓","UPRO":"三倍做多标普500ETF","AAPL":"苹果","BK4559":"巴菲特持仓","ZM":"Zoom","BK4550":"红杉资本持仓","SDS":"两倍做空标普500ETF","OEF":"标普100指数ETF-iShares","COMP":"Compass, Inc.","SH":"标普500反向ETF","SSO":"两倍做多标普500ETF","BK4504":"桥水持仓","MSFT":"微软",".DJI":"道琼斯","SPXU":"三倍做空标普500ETF",".IXIC":"NASDAQ Composite","OEX":"标普100",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185306806","content_text":"* Financials rally on rate hike expectations\n* Higher Treasury yields pressure tech stocks\n* Apple hits record high, JPM sees iPhone supply improving\nNov 22 (Reuters) - The S&P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.\nThe Dow Jones Industrial Average ended slightly higher.\nClimbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late in the session.\nApple ended up 0.3%, its highest closing level ever, after rising over 3% earlier in the day. JPMorgan flagged possible improvements to the supply of the iPhone 13 in coming months.\nMicrosoft ended down almost 1% after earlier rising almost 2%.\n\"The market is nervous. We know we have Powell, but that doesn't help with the inflation issue,\" said Dennis Dick, a trader at Bright Trading LLC. \"Under the hood, growth tech got hit all day, and then all of tech got hit at the end.\"\nPowell's nomination was welcomed by many investors hoping for no big changes in the Fed as it guides the economy through a recovery from the pandemic. The central bank is set to herald a return to pre-pandemic policy by end-2022.\nFed Governor Lael Brainard, who was the other top candidate for the job, will be vice chair, the White House said.\n\"Markets like predictability. ... While Brainard may have been a fine choice, the markets would not know what to expect from her even though the general consensus was that it meant lower rates for longer,\" said Randy Frederick, managing director of trading and derivatives at Charles Schwab in Austin, Texas.\nThe S&P 500 banks index rallied 2%, tracking a surge in Treasury yields as investors priced in policy tightening by the first half of 2022. Wells Fargo & Co rose over 3% and was among the strongest major Wall Street banks.\nFutures contracts tied to the Fed's policy rate indicated that money markets are now expecting the U.S. central bank to raise interest rates by 25 basis points by next June versus a previous estimate of July.\nThe Dow Jones Industrial Average rose 0.05% to end at 35,619.25 points, while the S&P 500 lost 0.32% to 4,682.94.\nThe Nasdaq Composite dropped 1.26% to 15,854.76.\nThe S&P 500 value index climbed 0.6%, strongly outperforming the S&P 500 growth index's 1% dip.\nIn extended trade, Zoom Video Communications fell 3% after the video-conferencing company posted quarterly revenue that beat expectations.\nInvestors were awaiting a slew of economic data this week, including IHS business activity readings, personal consumption expenditure, and minutes of the Fed's latest meeting.\nIn Monday's session, Amazon fell 2.8% and Alphabet declined 1.8%, both weighing heavily on the Nasdaq.\nTesla Inc gained 1.7% after CEO Elon Musk tweeted that the Model S Plaid will \"probably\" be coming to China around March. The stock has almost recovered from a steep selloff earlier this month that started after Musk polled Twitter users about whether he should sell some of his shares in the electric car maker.\nActivision Blizzard slipped 0.3% after a media report that the video game publisher's chief executive, Bobby Kotick, would consider leaving if he could not quickly address concerns about company culture.\nThe S&P 500 has now gained about 25% in 2021, while the Nasdaq is up 23%.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.76-to-1 ratio favored decliners.\nThe S&P 500 posted 52 new 52-week highs and 11 new lows; the Nasdaq Composite recorded 138 new highs and 507 new lows.\nVolume on U.S. exchanges was 11.6 billion shares, compared with the 11.1 billion average for the full session over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":607178331,"gmtCreate":1639518553383,"gmtModify":1639518575321,"author":{"id":"4093776015978190","authorId":"4093776015978190","name":"UNknown","avatar":"https://static.tigerbbs.com/544ab1c11c2e3063efc979d573c9bf0f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok thanks","listText":"Ok thanks","text":"Ok thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607178331","repostId":"1195286060","repostType":4,"isVote":1,"tweetType":1,"viewCount":608,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877499076,"gmtCreate":1637968372606,"gmtModify":1637968796763,"author":{"id":"4093776015978190","authorId":"4093776015978190","name":"UNknown","avatar":"https://static.tigerbbs.com/544ab1c11c2e3063efc979d573c9bf0f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good thanks&nbsp;","listText":"Good thanks&nbsp;","text":"Good thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877499076","repostId":"2186334897","repostType":4,"repost":{"id":"2186334897","pubTimestamp":1637936520,"share":"https://www.laohu8.com/m/news/2186334897?lang=&edition=full","pubTime":"2021-11-26 22:22","market":"us","language":"en","title":"Prediction: These 2 Stocks Will Soar in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2186334897","media":"Motley Fool","summary":"These two stocks were battered in 2021, but 2022 could be a different story.","content":"<p>The stock market has been performing amazingly well in 2021. The <b>SPDR S&amp;P 500 ETF</b>&nbsp;has been at or near an all-time high all year, with its biggest drop being in October when it fell 5%.&nbsp;But not all stocks have followed a similar path. Some have fallen up to 70% off their all-time highs. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> of the biggest names that got crushed in 2021 were <b>Pinterest</b> (NYSE:PINS) and <b>Lemonade</b> (NYSE:LMND) -- falling 52% and 72% off their highs, respectively.</p>\n<p>Despite their falls, both companies have strong potential and made substantial business progress while their stocks were pounded. This progress might pay off in 2022, which could send their stocks up to all-time highs.</p>\n<h2>1. Pinterest is not an MAU story</h2>\n<p>Shares of the social media company have gotten hammered in 2021, slowly falling from the highs they hit in the first few months of the year. The company was up against tough 2020 comparables in its earnings reports. The use of Pinterest rose drastically during the COVID-19 pandemic, but as the world slowly reopened, the company saw slower growth internationally and even a decreasing user count in the U.S.</p>\n<p>In Q3 2020, for example, Pinterest has 98 million U.S. monthly active users (MAUs), but that decreased to 89 million in Q3 2021. In Q4 2020, Pinterest saw international MAU grow by 46%, compared to Q3 2021 growth of just 4%.</p>\n<p>While many investors worry about this declining growth, this isn't the primary key to success for Pinterest. The real opportunity for Pinterest is in the increased monetization of its MAUs. Pinterest has plenty of room for expansion of its average revenue per user (ARPU), especially when its ARPU of $1.41 is compared to other social media stocks. <b>Snapchat</b> (NYSE:SNAP) has an ARPU of $3.49, and <b><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a></b>' (NASDAQ:FB) ARPU is a whopping $10.</p>\n<p>The company has made important strides during 2021 to increase this monetization. One of those was Pinterest TV -- where creators can sell products from a video -- as well as efforts to make it easier for users to add items to a cart to buy later.</p>\n<p>This increased effort makes advertising on Pinterest more valuable to advertisers, and if these efforts are effective at increasing its ARPU in 2022, investors could see accelerating revenue growth. Currently, the company is growing ARPU at 37% year over year, but the company has the potential to hasten this growth. If the improved efforts are successful, Pinterest could experience significant revenue growth, which could finally make Pinterest a favorable investment again in 2022 and send shares soaring.</p>\n<h2>2. Lemonade's future is bright despite current losses</h2>\n<p>Like Pinterest, shares of the AI-based insurance company have been hammered in 2021. Almost six months after its initial public offering (IPO) in July 2020, the company saw shares skyrocket, jumping over 120% by the start of 2021. However, the hype of the IPO faded, and a tough first quarter due to the Texas freeze (failures in the natural gas infrastructure system that nearly halved the state's gas production) started a downturn that resulted in shares falling 71% off its all-time high.</p>\n<p>The Texas freeze hit Lemonade's net loss ratio, which shows how much the company has to pay in claims for how much it earns in premiums. In Q1, Lemonade's loss ratio reached 121%, meaning that the company paid out significantly more than the money it made in claims (not the best business model). Since Q1, its net loss has decreased, but it is still higher than what the company is aiming for. In Q3, the company's loss ratio was 77%, but the company says its loss ratio should be under 75% in the long term.</p>\n<p>Part of the reason the loss ratio was above 75% in Q3 was because of the rollout of its newer products, like car and pet insurance. The AI for Lemonade's newer products is still being fine-tuned, which is currently resulting in a higher net loss ratio for those products. Yet, despite the loss ratios being high, they are improving rapidly. The pet loss ratio improved by 4 percentage points sequentially, while the homeowners' loss ratio improved by 52 percentage points year over year.</p>\n<p>Clearly, there are trends showing that Lemonade's AI is getting more accurate with its newer products. And as these products mature and the AI gets more precise, investors will likely see these loss ratios improve substantially. The loss ratio has the potential to fall below the 75% threshold, which could help Lemonade rise again and turn investor sentiment positively toward the company.</p>\n<p>The bottom line for both companies is that investors fell out of love with them. Since the reasons they lost hype do not fully represent the company's success, the tide could turn in 2022. If each company's investments into its business in 2021 pay off, today might be a nice buying opportunity to reap benefits going into the new year.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prediction: These 2 Stocks Will Soar in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrediction: These 2 Stocks Will Soar in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/26/prediction-these-two-stocks-will-soar-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market has been performing amazingly well in 2021. The SPDR S&P 500 ETF has been at or near an all-time high all year, with its biggest drop being in October when it fell 5%. But not all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/26/prediction-these-two-stocks-will-soar-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LMND":"Lemonade, Inc.","BK4548":"巴美列捷福持仓","BK4107":"财产与意外伤害保险","BK4554":"元宇宙及AR概念","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BK4507":"流媒体概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4525":"远程办公概念","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4524":"宅经济概念","BK4508":"社交媒体","BK4527":"明星科技股","PINS":"Pinterest, Inc.","BK4077":"互动媒体与服务","BK4550":"红杉资本持仓","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4549":"软银资本持仓"},"source_url":"https://www.fool.com/investing/2021/11/26/prediction-these-two-stocks-will-soar-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186334897","content_text":"The stock market has been performing amazingly well in 2021. The SPDR S&P 500 ETF has been at or near an all-time high all year, with its biggest drop being in October when it fell 5%. But not all stocks have followed a similar path. Some have fallen up to 70% off their all-time highs. Two of the biggest names that got crushed in 2021 were Pinterest (NYSE:PINS) and Lemonade (NYSE:LMND) -- falling 52% and 72% off their highs, respectively.\nDespite their falls, both companies have strong potential and made substantial business progress while their stocks were pounded. This progress might pay off in 2022, which could send their stocks up to all-time highs.\n1. Pinterest is not an MAU story\nShares of the social media company have gotten hammered in 2021, slowly falling from the highs they hit in the first few months of the year. The company was up against tough 2020 comparables in its earnings reports. The use of Pinterest rose drastically during the COVID-19 pandemic, but as the world slowly reopened, the company saw slower growth internationally and even a decreasing user count in the U.S.\nIn Q3 2020, for example, Pinterest has 98 million U.S. monthly active users (MAUs), but that decreased to 89 million in Q3 2021. In Q4 2020, Pinterest saw international MAU grow by 46%, compared to Q3 2021 growth of just 4%.\nWhile many investors worry about this declining growth, this isn't the primary key to success for Pinterest. The real opportunity for Pinterest is in the increased monetization of its MAUs. Pinterest has plenty of room for expansion of its average revenue per user (ARPU), especially when its ARPU of $1.41 is compared to other social media stocks. Snapchat (NYSE:SNAP) has an ARPU of $3.49, and Meta Platforms' (NASDAQ:FB) ARPU is a whopping $10.\nThe company has made important strides during 2021 to increase this monetization. One of those was Pinterest TV -- where creators can sell products from a video -- as well as efforts to make it easier for users to add items to a cart to buy later.\nThis increased effort makes advertising on Pinterest more valuable to advertisers, and if these efforts are effective at increasing its ARPU in 2022, investors could see accelerating revenue growth. Currently, the company is growing ARPU at 37% year over year, but the company has the potential to hasten this growth. If the improved efforts are successful, Pinterest could experience significant revenue growth, which could finally make Pinterest a favorable investment again in 2022 and send shares soaring.\n2. Lemonade's future is bright despite current losses\nLike Pinterest, shares of the AI-based insurance company have been hammered in 2021. Almost six months after its initial public offering (IPO) in July 2020, the company saw shares skyrocket, jumping over 120% by the start of 2021. However, the hype of the IPO faded, and a tough first quarter due to the Texas freeze (failures in the natural gas infrastructure system that nearly halved the state's gas production) started a downturn that resulted in shares falling 71% off its all-time high.\nThe Texas freeze hit Lemonade's net loss ratio, which shows how much the company has to pay in claims for how much it earns in premiums. In Q1, Lemonade's loss ratio reached 121%, meaning that the company paid out significantly more than the money it made in claims (not the best business model). Since Q1, its net loss has decreased, but it is still higher than what the company is aiming for. In Q3, the company's loss ratio was 77%, but the company says its loss ratio should be under 75% in the long term.\nPart of the reason the loss ratio was above 75% in Q3 was because of the rollout of its newer products, like car and pet insurance. The AI for Lemonade's newer products is still being fine-tuned, which is currently resulting in a higher net loss ratio for those products. Yet, despite the loss ratios being high, they are improving rapidly. The pet loss ratio improved by 4 percentage points sequentially, while the homeowners' loss ratio improved by 52 percentage points year over year.\nClearly, there are trends showing that Lemonade's AI is getting more accurate with its newer products. And as these products mature and the AI gets more precise, investors will likely see these loss ratios improve substantially. The loss ratio has the potential to fall below the 75% threshold, which could help Lemonade rise again and turn investor sentiment positively toward the company.\nThe bottom line for both companies is that investors fell out of love with them. Since the reasons they lost hype do not fully represent the company's success, the tide could turn in 2022. If each company's investments into its business in 2021 pay off, today might be a nice buying opportunity to reap benefits going into the new year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":276,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609055438,"gmtCreate":1638227210475,"gmtModify":1638227210655,"author":{"id":"4093776015978190","authorId":"4093776015978190","name":"UNknown","avatar":"https://static.tigerbbs.com/544ab1c11c2e3063efc979d573c9bf0f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609055438","repostId":"1182524223","repostType":4,"isVote":1,"tweetType":1,"viewCount":695,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875108597,"gmtCreate":1637622339591,"gmtModify":1637622339697,"author":{"id":"4093776015978190","authorId":"4093776015978190","name":"UNknown","avatar":"https://static.tigerbbs.com/544ab1c11c2e3063efc979d573c9bf0f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875108597","repostId":"2185306806","repostType":4,"repost":{"id":"2185306806","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1637620044,"share":"https://www.laohu8.com/m/news/2185306806?lang=&edition=full","pubTime":"2021-11-23 06:27","market":"us","language":"en","title":"Nasdaq and S&P 500 end down after hitting record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=2185306806","media":"Reuters","summary":"* Apple hits record high, JPM sees iPhone supply improving. Nov 22  - The S&P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.The Dow Jones Industrial Average ended slightly higher.Climbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late ","content":"<p>* Financials rally on rate hike expectations</p>\n<p>* Higher Treasury yields pressure tech stocks</p>\n<p>* Apple hits record high, JPM sees iPhone supply improving</p>\n<p>Nov 22 (Reuters) - The S&amp;P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.</p>\n<p>The Dow Jones Industrial Average ended slightly higher.</p>\n<p>Climbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late in the session.</p>\n<p>Apple ended up 0.3%, its highest closing level ever, after rising over 3% earlier in the day. JPMorgan flagged possible improvements to the supply of the iPhone 13 in coming months.</p>\n<p>Microsoft ended down almost 1% after earlier rising almost 2%.</p>\n<p>\"The market is nervous. We know we have Powell, but that doesn't help with the inflation issue,\" said Dennis Dick, a trader at Bright Trading LLC. \"Under the hood, growth tech got hit all day, and then all of tech got hit at the end.\"</p>\n<p>Powell's nomination was welcomed by many investors hoping for no big changes in the Fed as it guides the economy through a recovery from the pandemic. The central bank is set to herald a return to pre-pandemic policy by end-2022.</p>\n<p>Fed Governor Lael Brainard, who was the other top candidate for the job, will be vice chair, the White House said.</p>\n<p>\"Markets like predictability. ... While Brainard may have been a fine choice, the markets would not know what to expect from her even though the general consensus was that it meant lower rates for longer,\" said Randy Frederick, managing director of trading and derivatives at Charles Schwab in Austin, Texas.</p>\n<p>The S&amp;P 500 banks index rallied 2%, tracking a surge in Treasury yields as investors priced in policy tightening by the first half of 2022. Wells Fargo &amp; Co rose over 3% and was among the strongest major Wall Street banks.</p>\n<p>Futures contracts tied to the Fed's policy rate indicated that money markets are now expecting the U.S. central bank to raise interest rates by 25 basis points by next June versus a previous estimate of July.</p>\n<p>The Dow Jones Industrial Average rose 0.05% to end at 35,619.25 points, while the S&amp;P 500 lost 0.32% to 4,682.94.</p>\n<p>The Nasdaq Composite dropped 1.26% to 15,854.76.</p>\n<p>The S&amp;P 500 value index climbed 0.6%, strongly outperforming the S&amp;P 500 growth index's 1% dip.</p>\n<p>In extended trade, <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications fell 3% after the video-conferencing company posted quarterly revenue that beat expectations.</p>\n<p>Investors were awaiting a slew of economic data this week, including IHS business activity readings, personal consumption expenditure, and minutes of the Fed's latest meeting.</p>\n<p>In Monday's session, Amazon fell 2.8% and Alphabet declined 1.8%, both weighing heavily on the Nasdaq.</p>\n<p>Tesla Inc gained 1.7% after CEO Elon Musk tweeted that the Model S Plaid will \"probably\" be coming to China around March. The stock has almost recovered from a steep selloff earlier this month that started after Musk polled <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> users about whether he should sell some of his shares in the electric car maker.</p>\n<p>Activision Blizzard slipped 0.3% after a media report that the video game publisher's chief executive, Bobby Kotick, would consider leaving if he could not quickly address concerns about company culture.</p>\n<p>The S&amp;P 500 has now gained about 25% in 2021, while the Nasdaq is up 23%.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.76-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 52 new 52-week highs and 11 new lows; the Nasdaq Composite recorded 138 new highs and 507 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, compared with the 11.1 billion average for the full session over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq and S&P 500 end down after hitting record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq and S&P 500 end down after hitting record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-11-23 06:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Financials rally on rate hike expectations</p>\n<p>* Higher Treasury yields pressure tech stocks</p>\n<p>* Apple hits record high, JPM sees iPhone supply improving</p>\n<p>Nov 22 (Reuters) - The S&amp;P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.</p>\n<p>The Dow Jones Industrial Average ended slightly higher.</p>\n<p>Climbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late in the session.</p>\n<p>Apple ended up 0.3%, its highest closing level ever, after rising over 3% earlier in the day. JPMorgan flagged possible improvements to the supply of the iPhone 13 in coming months.</p>\n<p>Microsoft ended down almost 1% after earlier rising almost 2%.</p>\n<p>\"The market is nervous. We know we have Powell, but that doesn't help with the inflation issue,\" said Dennis Dick, a trader at Bright Trading LLC. \"Under the hood, growth tech got hit all day, and then all of tech got hit at the end.\"</p>\n<p>Powell's nomination was welcomed by many investors hoping for no big changes in the Fed as it guides the economy through a recovery from the pandemic. The central bank is set to herald a return to pre-pandemic policy by end-2022.</p>\n<p>Fed Governor Lael Brainard, who was the other top candidate for the job, will be vice chair, the White House said.</p>\n<p>\"Markets like predictability. ... While Brainard may have been a fine choice, the markets would not know what to expect from her even though the general consensus was that it meant lower rates for longer,\" said Randy Frederick, managing director of trading and derivatives at Charles Schwab in Austin, Texas.</p>\n<p>The S&amp;P 500 banks index rallied 2%, tracking a surge in Treasury yields as investors priced in policy tightening by the first half of 2022. Wells Fargo &amp; Co rose over 3% and was among the strongest major Wall Street banks.</p>\n<p>Futures contracts tied to the Fed's policy rate indicated that money markets are now expecting the U.S. central bank to raise interest rates by 25 basis points by next June versus a previous estimate of July.</p>\n<p>The Dow Jones Industrial Average rose 0.05% to end at 35,619.25 points, while the S&amp;P 500 lost 0.32% to 4,682.94.</p>\n<p>The Nasdaq Composite dropped 1.26% to 15,854.76.</p>\n<p>The S&amp;P 500 value index climbed 0.6%, strongly outperforming the S&amp;P 500 growth index's 1% dip.</p>\n<p>In extended trade, <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications fell 3% after the video-conferencing company posted quarterly revenue that beat expectations.</p>\n<p>Investors were awaiting a slew of economic data this week, including IHS business activity readings, personal consumption expenditure, and minutes of the Fed's latest meeting.</p>\n<p>In Monday's session, Amazon fell 2.8% and Alphabet declined 1.8%, both weighing heavily on the Nasdaq.</p>\n<p>Tesla Inc gained 1.7% after CEO Elon Musk tweeted that the Model S Plaid will \"probably\" be coming to China around March. The stock has almost recovered from a steep selloff earlier this month that started after Musk polled <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> users about whether he should sell some of his shares in the electric car maker.</p>\n<p>Activision Blizzard slipped 0.3% after a media report that the video game publisher's chief executive, Bobby Kotick, would consider leaving if he could not quickly address concerns about company culture.</p>\n<p>The S&amp;P 500 has now gained about 25% in 2021, while the Nasdaq is up 23%.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.76-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 52 new 52-week highs and 11 new lows; the Nasdaq Composite recorded 138 new highs and 507 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, compared with the 11.1 billion average for the full session over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SPY":"标普500ETF","IVV":"标普500指数ETF","BK4534":"瑞士信贷持仓","UPRO":"三倍做多标普500ETF","AAPL":"苹果","BK4559":"巴菲特持仓","ZM":"Zoom","BK4550":"红杉资本持仓","SDS":"两倍做空标普500ETF","OEF":"标普100指数ETF-iShares","COMP":"Compass, Inc.","SH":"标普500反向ETF","SSO":"两倍做多标普500ETF","BK4504":"桥水持仓","MSFT":"微软",".DJI":"道琼斯","SPXU":"三倍做空标普500ETF",".IXIC":"NASDAQ Composite","OEX":"标普100",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185306806","content_text":"* Financials rally on rate hike expectations\n* Higher Treasury yields pressure tech stocks\n* Apple hits record high, JPM sees iPhone supply improving\nNov 22 (Reuters) - The S&P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.\nThe Dow Jones Industrial Average ended slightly higher.\nClimbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late in the session.\nApple ended up 0.3%, its highest closing level ever, after rising over 3% earlier in the day. JPMorgan flagged possible improvements to the supply of the iPhone 13 in coming months.\nMicrosoft ended down almost 1% after earlier rising almost 2%.\n\"The market is nervous. We know we have Powell, but that doesn't help with the inflation issue,\" said Dennis Dick, a trader at Bright Trading LLC. \"Under the hood, growth tech got hit all day, and then all of tech got hit at the end.\"\nPowell's nomination was welcomed by many investors hoping for no big changes in the Fed as it guides the economy through a recovery from the pandemic. The central bank is set to herald a return to pre-pandemic policy by end-2022.\nFed Governor Lael Brainard, who was the other top candidate for the job, will be vice chair, the White House said.\n\"Markets like predictability. ... While Brainard may have been a fine choice, the markets would not know what to expect from her even though the general consensus was that it meant lower rates for longer,\" said Randy Frederick, managing director of trading and derivatives at Charles Schwab in Austin, Texas.\nThe S&P 500 banks index rallied 2%, tracking a surge in Treasury yields as investors priced in policy tightening by the first half of 2022. Wells Fargo & Co rose over 3% and was among the strongest major Wall Street banks.\nFutures contracts tied to the Fed's policy rate indicated that money markets are now expecting the U.S. central bank to raise interest rates by 25 basis points by next June versus a previous estimate of July.\nThe Dow Jones Industrial Average rose 0.05% to end at 35,619.25 points, while the S&P 500 lost 0.32% to 4,682.94.\nThe Nasdaq Composite dropped 1.26% to 15,854.76.\nThe S&P 500 value index climbed 0.6%, strongly outperforming the S&P 500 growth index's 1% dip.\nIn extended trade, Zoom Video Communications fell 3% after the video-conferencing company posted quarterly revenue that beat expectations.\nInvestors were awaiting a slew of economic data this week, including IHS business activity readings, personal consumption expenditure, and minutes of the Fed's latest meeting.\nIn Monday's session, Amazon fell 2.8% and Alphabet declined 1.8%, both weighing heavily on the Nasdaq.\nTesla Inc gained 1.7% after CEO Elon Musk tweeted that the Model S Plaid will \"probably\" be coming to China around March. The stock has almost recovered from a steep selloff earlier this month that started after Musk polled Twitter users about whether he should sell some of his shares in the electric car maker.\nActivision Blizzard slipped 0.3% after a media report that the video game publisher's chief executive, Bobby Kotick, would consider leaving if he could not quickly address concerns about company culture.\nThe S&P 500 has now gained about 25% in 2021, while the Nasdaq is up 23%.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.76-to-1 ratio favored decliners.\nThe S&P 500 posted 52 new 52-week highs and 11 new lows; the Nasdaq Composite recorded 138 new highs and 507 new lows.\nVolume on U.S. exchanges was 11.6 billion shares, compared with the 11.1 billion average for the full session over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":414,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604335713,"gmtCreate":1639347381504,"gmtModify":1639347381660,"author":{"id":"4093776015978190","authorId":"4093776015978190","name":"UNknown","avatar":"https://static.tigerbbs.com/544ab1c11c2e3063efc979d573c9bf0f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604335713","repostId":"2188532153","repostType":2,"isVote":1,"tweetType":1,"viewCount":356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609544749,"gmtCreate":1638314157014,"gmtModify":1638314157014,"author":{"id":"4093776015978190","authorId":"4093776015978190","name":"UNknown","avatar":"https://static.tigerbbs.com/544ab1c11c2e3063efc979d573c9bf0f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok&nbsp;Thanks&nbsp;","listText":"Ok&nbsp;Thanks&nbsp;","text":"Ok Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609544749","repostId":"1192203085","repostType":4,"repost":{"id":"1192203085","pubTimestamp":1638273550,"share":"https://www.laohu8.com/m/news/1192203085?lang=&edition=full","pubTime":"2021-11-30 19:59","market":"us","language":"en","title":"Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates","url":"https://stock-news.laohu8.com/highlight/detail?id=1192203085","media":"The Wall Street Journal","summary":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA ","content":"<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p>\n<p>Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p>\n<p>Separate testing of another authorized Covid-19 antibody drug cocktail, from&nbsp;Eli Lilly&amp; Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p>\n<p>The findings are the early results of researchers’ race to assess the impact of the&nbsp;new Omicron variant&nbsp;on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p>\n<p>Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p>\n<p>Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p>\n<p>They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p>\n<p>The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former&nbsp;President Donald Trump credited Regeneron’s drug&nbsp;with his speedy recovery from Covid-19.</p>\n<p>Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p>\n<p>If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p>\n<p>One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p>\n<p>The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p>\n<p>“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p>\n<p>Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p>\n<p>More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p>\n<p>Lilly is in the process of testing the new variant against its drug, a combination of&nbsp;two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p>\n<p>She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p>\n<p>“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p>\n<p>A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including&nbsp;Vir Biotechnology&nbsp;Inc.&nbsp;and GlaxoSmithKline PLC, whose drug&nbsp;sotrovimab was authorized for emergency use&nbsp;earlier this year.</p>\n<p>Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p>\n<p>Adagio Therapeutics&nbsp;Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p>\n<p>Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p>\n<p>Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p>\n<p>Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p>\n<p>“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p>\n<p>It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p>\n<p>“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p>\n<p>Antiviral drugs, including pills from&nbsp;Merck&amp; Co. and partner Ridgeback Biotherapeutics LP and from&nbsp;Pfizer&nbsp;Inc.&nbsp;that are being&nbsp;evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p>\n<p>Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have&nbsp;reduced the risk of hospitalization&nbsp;if taken early enough.</p>\n<p>“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p>\n<p>Pfizer and Merck said they expect their drugs to be effective against Omicron.</p>\n<p>Gilead SciencesInc.&nbsp;also said it expects&nbsp;Veklury, its antiviral drug&nbsp;used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCovid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests ...</p>\n\n<a href=\"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","REGN":"再生元制药公司"},"source_url":"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192203085","content_text":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.\nSeparate testing of another authorized Covid-19 antibody drug cocktail, from Eli Lilly& Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.\nThe findings are the early results of researchers’ race to assess the impact of the new Omicron variant on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.\nResearchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.\nMonoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.\nThey are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.\nThe drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former President Donald Trump credited Regeneron’s drug with his speedy recovery from Covid-19.\nRegeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.\nAntiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.\nIf final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.\nOne of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.\nThe Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.\n“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”\nScientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.\nMore comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.\nLilly is in the process of testing the new variant against its drug, a combination of two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.\nShe declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.\n“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”\nA rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including Vir Biotechnology Inc. and GlaxoSmithKline PLC, whose drug sotrovimab was authorized for emergency use earlier this year.\nFred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.\nAdagio Therapeutics Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.\nVir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.\nOmicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.\nVir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.\n“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.\nIt will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.\n“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”\nAntiviral drugs, including pills from Merck& Co. and partner Ridgeback Biotherapeutics LP and from Pfizer Inc. that are being evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.\nDoctors and patients have been looking forward to authorization of the pills, which in clinical trials have reduced the risk of hospitalization if taken early enough.\n“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.\nPfizer and Merck said they expect their drugs to be effective against Omicron.\nGilead SciencesInc. also said it expects Veklury, its antiviral drug used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.","news_type":1},"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}